Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 19, 2024 · Filed Nov 21, 2024
A Humacyte director paid $8K out of pocket for Humacyte shares. 2 other people at Humacyte bought some too, in the same month. It was the first purchase in over a year.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$7,979
Shares × reported transaction price
<$25K
+0.7%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
None in 13 months of history
Confirmed open-market purchases by the same insider in the available history
3 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
11 days after results of Nov 8, 2024
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.7% | +1.2% | −0.5% |
| 30 days | +3.6% | −0.1% | +3.7% |
| 90 days | −16.5% | +2.5% | −19.0% |
| 180 days | −47.9% | −2.1% | −45.8% |
| 365 days | −71.5% | +12.3% | −83.8% |
Past results only. Not a forecast.
Insider buying
Traded Dec 4, 2024 · filed the same day
A Humacyte director paid $20K out of pocket for Humacyte shares. 2 other people at Humacyte bought some too, in the same month. It was the first purchase in over a year.
Insider selling
Traded Nov 18, 2024 · filed 3 days laterNot reported under a pre-arranged trading plan
A Humacyte director sold $3.6M of Humacyte shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Nov 19, 2024 · filed 2 days laterNot reported under a pre-arranged trading plan
A Humacyte director sold $1.86M of Humacyte shares. The filing does not indicate a pre-arranged trading plan.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.